3 Abstract Purpose: New therapies are urgently needed for patients with acute myeloid leukemia (AML). The novel NEDDylation inhibitor MLN4924 (pevonedistat) has demonstrated significant preclinical anti-leukemic activity and preliminary efficacy in patients with AML in a Phase I trial. Based on its anti-myeloid and DNA-damaging properties, we investigated the ability of MLN4924 to augment conventional cytarabine (ara-C) therapy.
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Introduction
Acute myeloid leukemia (AML) is a multi-step, multi-pathway malignancy that is ultimately fatal in the majority of affected patients (1) . Older adults with AML have an extremely poor prognosis and derive limited benefit from intensive chemotherapy due to their prevalence of unfavorable cytogenetics predicting chemotherapy refractoriness, pre-existing myelodysplastic syndromes (MDS) associated with a limited normal functioning stem cell compartment and serial genetic lesions evolving to disease manifestation, and expression of a multidrug resistant phenotype (2) (3) (4) . No standard induction approach exists for older adults, due in part, to their poor representation in clinical studies. The last prospective trial comparing intensive chemotherapy to lowdose approaches was conducted over two decades ago (5) Protein turnover plays a critical regulatory role in many essential cellular processes including cell cycle progression, signal transduction, and cell death. Aberrant ubiquitinproteasome system (UPS)-mediated protein degradation contributes to disease progression, metastasis, and drug resistance and is thus, an appealing anticancer strategy (6) . The proteasome inhibitor, bortezomib (Velcade), was the first anticancer Author Manuscript Published OnlineFirst on November 11, 2014; DOI: 10.1158/1078-0432.CCR- 5 agent of this drug class to receive FDA approval (7) . Bortezomib established proof of concept that targeting protein turnover is an effective anticancer strategy and is currently indicated for the treatment of multiple myeloma and mantle cell lymphoma and in combination with cytotoxic therapy, yielded high response rates in AML patients (8, 9) . Following its success, a second proteasome inhibitor (carfilzomib) also earned FDA approval for the treatment of multiple myeloma patients who progressed following treatment with bortezomib and an immunomodulatory drug (10) . More recent drug discovery efforts have focused on the development of novel agents that target key regulators of the UPS system. A major objective of this approach is to disrupt the turnover of selected subsets of proteins, which could potentially eliminate or reduce some of the off-target effects and toxicities that are associated with global proteasomal inhibition.
NEDD8 is a small ubiquitin-like (UBL) molecule that regulates the activity of the cullin-RING family of E3 ubiquitin ligases (CRLs) through covalent modification. The CRLs control the degradation of a number of proteins with essential roles in cell cycle progression, tumor suppression, signal transduction, and responses to DNA damage and other stress stimuli including p27, cyclin E, c-Myc, p53, phospho-IκBα, CDT-1, NRF-2, and HIF-1α (11) . As degradation of these molecules could accelerate cancer progression and/or promote therapeutic resistance, disrupting the NEDDylation pathway has significant and logical therapeutic potential. MLN4924 (pevonedistat) is a first-inclass, selective small molecule inhibitor of NEDD8 activating enzyme (NAE), the proximal regulator of the NEDDylation cascade (12) (13) (14) . We previously showed that (15) . This was confirmed in a Phase I clinical trial in refractory MDS/AML patients, some of whom achieved complete responses following treatment with MLN4924 (16) . The mechanistic basis for the anti-AML effects of MLN4924 remains to be fully elucidated. We conducted comprehensive metabolic profiling to further investigate the pharmacodynamic effects of MLN4924 in AML cells that contribute to its therapeutic activity and ability to augment the efficacy of ara-C.
Materials & Methods
Cells and cell culture. HL-60 and KG-1 cells were obtained from ATCC (Manassas, VA). MV4-11 and MOLM-13 cells were obtained from DSMZ (Braunschweig, Germany).
Cell lines were authenticated by the source banks using DNA profiling techniques and were used for this study in accordance with AACR guidelines. Primary human AML cells were isolated from the bone marrow of AML patients after obtaining informed consent.
All AML cells (primary and established cell lines) were cultured under identical conditions with RPMI 1640 medium supplemented with 10% FBS at 37°C with 5% CO 2 as previously described (15) . Cell viability assay. Cells were plated in triplicate and treated with defined concentrations of MLN4924, ara-C, or both drugs for 72 hours. Viable cells were quantified using ATPLite according to the manufacturer's instructions (Perkin Elmer, Waltham, MA) as previously described (14, 15, 17) . Author Manuscript Published OnlineFirst on November 11, 2014; DOI: 10.1158/1078-0432.CCR- Analysis of drug-induced apoptosis. Drug-induced apoptosis was quantified by PI/FACS analysis of sub-G 0 /G 1 DNA content as previously described (17, 19) .
Colony assays. AML cells were treated with the indicated concentrations of MLN4924, ara-C or both drugs for 24h. Drugs were washed away and cells were seeded in Methocult methylcellulose-containing medium. Colonies were stained and scored as previously described (15, 20) .
Immunoblotting. AML cells were incubated with MLN4924, ara-C, or the combination of both drugs for 24 h as indicated. Cells were then lysed for 1 h on ice in Triton X-100 lysis buffer (1% triton X-100, 150 mM NaCl, 25 mM Tris pH 7.5) with protease inhibitors.
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes.
Blots were probed with the indicated antibodies and bands were detected by enhanced chemiluminescence (Alpha Innotech, San Leandro, CA) as previously described (21) . β-tubulin documented equal loading.
Alkaline comet assay. AML cells were treated with MLN4924, ara-C, or both drugs for 24 h. Comet assays were performed using the CometAssay® kit (Trevigen, Gaithersburg, MD) according to the manufacturer's instructions as previously described (17) . Cells were imaged using fluorescent microscopy and tail moments (product of DNA amount in tail and distance of tail migration) from 50 cells per slide were calculated. Immunohistochemistry. Paraffin-embedded tumor sections were deparaffinized in xylene, exposed to a graded series of alcohol, and rehydrated in PBS (pH 7.5). Heatinduced epitope retrieval on paraffin-embedded sections and probing with specific antibodies was conducted as previously described (17) . Positive reactions were visualized using 3,3'-diaminobenzidine (Dako, Glostrup, Denmark). Images were captured using an Olympus fluorescent microscope (Center Valley, PA) with a DP71 camera and a 20X objective. Image-Pro Plus software Version 6.2.1 (MediaCybernetics, Bethesda, MD) was used for image acquisition. ImageJ software was used for quantification of γH2AX and p27 levels by densitometric analysis of five random fields containing viable tumor cells. Quantification of PCNA and cleaved caspase-3 was conducted by counting the number of positive cells in five random fields as previously described (25) .
Statistical analyses. Statistical significance of differences observed between samples was determined using the Tukey-Kramer Comparison Test or the Student's t test.
Differences were considered significant in all experiments at p < 0.05 with two-sided comparisons.
Results
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Author Manuscript Published OnlineFirst on November 11, 2014; DOI: 10.1158/1078-0432.CCR- MLN4924 and ara-C cooperate to antagonize clonogenic survival and trigger apoptosis. To investigate inhibiting NEDDylation with MLN4924 as a novel approach to increase the anti-AML activity of ara-C, we first treated 4 human AML cell lines (MV4-11, MOLM-13, HL-60, KG-1) with MLN4924, ara-C, or both drugs for 72 h and quantified the resulting impact of drug exposure on cell viability by ATPLite assay. Pilot drug sequencing studies showed that pre-treatment with one drug first for 24 h followed by the other agent for the remainder of the assay period did not yield significantly different anti-leukemic effects as compared with simultaneous drug treatment (not shown). We therefore used simultaneous treatment conditions for all in vitro combination assays in this study. Combined treatment with MLN4924 and ara-C reduced cell viability significantly more effectively than either single agent (Fig. 1A) . Author Manuscript Published OnlineFirst on November 11, 2014; DOI: 10.1158/1078-0432.CCR- greater diminished clonogenic survival (Fig. 1C) and levels of drug-induced apoptosis (Fig. 1D ) than exposure to either drug alone.
The combination of MLN4924 and ara-C promotes increased levels of DNA damage. The induction of DNA damage is one of the hallmark features of the anticancer mechanism of action of ara-C and other nucleoside analogs. We and others have also demonstrated that MLN4924 triggers DNA damage by promoting CDT-1 dependent DNA re-replication (15, 17, 26) . We hypothesized that co-treatment with MLN4924 and ara-C would yield significantly greater levels of DNA damage.
Accordingly, MLN924 and ara-C cooperated to stimulate increased levels of the phosphorylated (active) form of the DNA damage sensor CHK1 (Ser317), and the DNA damage marker H2AX (Fig. 2A) . These effects coincided with an elevation in the expression of the cyclin-dependent kinase inhibitor p27 and the active form of caspase-3, which would be expected based upon the combined effects of these agents on cell viability and apoptosis shown in Fig. 1 . We next conducted alkaline comet assays to generate another readout of drug-induced DNA damage. These experiments demonstrated that the MLN4924/ara-C combination significantly increased the DNA tail moment, indicating heightened levels of DNA damage (Fig. 2B-C) . 13 whether this specific effect may be responsible, at least in part, for the benefit we observed with the MLN4924/ara-C combination, we utilized shRNA to target is expression in MOLM-13 cells. Knockdown efficiency was assessed by immunoblotting (Fig. 3A) . A comparison of the pro-apoptotic effects of the MLN4924/ara-C combination in the presence and absence of CDT1 shRNA showed that CDT1 expression levels had a modest impact on single agent MLN4924 treatment, but had a negligible effect on the combination of both drugs (Fig. 3B) . These results suggest that other aspects of the mechanism of action of MLN4924 may be mediating its ability to augment ara-C activity. Author Manuscript Published OnlineFirst on November 11, 2014; DOI: 10.1158/1078-0432.CCR- Additional statistical analyses revealed that the nucleotide biosynthesis superpathway was one of the most altered overall pathways following treatment with MLN4924.
Heatmap analysis (Fig. 4B) and quantification of the effects of drug treatment on the levels of individual nucleotide pathway components (Suppl. Fig. 1 
MLN4924 facilitates increased incorporation of ara-C into the DNA of AML cells.
We hypothesized that the therapeutic benefit derived from combining MLN4924 with ara-C could be due, in part, to increased DNA incorporation of ara-C facilitated by reduced competition from endogenous nucleotides/nucleosides. To test this possibility, we quantified the inclusion of radiolabeled [ (Fig. 5B) . Our collective results demonstrate that the combination benefit of MLN4924 and ara-C is at least partially due to elevated incorporation of ara-C into the DNA of AML cells.
The combination of MLN4924 and ara-C effectively inhibits the progression of

FLT3-ITD+ AML xenografts in vivo.
The in vivo anticancer activity of the MLN4924/ara-C combination was evaluated by administering vehicle control, MLN4924
(60 mg/kg BID), ara-C (50 mg/kg QD), or both drugs to mice implanted with MOLM-13 FLT3-ITD+ xenografts. Both MLN4924 and ara-C monotherapies significantly inhibited disease progression (Fig. 6A) . Co-administration of MLN4924 and ara-C provided a significantly greater therapeutic benefit than either drug alone and resulted in stable inhibition of disease progression throughout our study. The combination was well tolerated and no notable toxicities were observed other than a very modest reduction in Author Manuscript Published OnlineFirst on November 11, 2014; DOI: 10.1158/1078-0432.CCR- apoptosis (cleaved caspase-3) following treatment with the MLN4924/ara-C combination compared to either single agent (Fig. 6B, Suppl. Fig. 4 ).
Discussion
Cytotoxic-based therapy remains the standard for the treatment of AML, and has changed little in the past four decades. New agents/strategies for AML therapy are clearly needed in general, but are urgently required for patients that have unfavorable cytogenetics and/or are older and unfit for cytotoxic induction chemotherapy as they have the lowest probability of achieving long-term survival (<20%) with existing therapies (4, 27, 28) . Inhibition of the NEDDylation pathway with the investigational drug MLN4924 is a novel therapeutic approach that has demonstrated encouraging anti-AML activity in the preclinical and clinical setting (15, 16) .
However, our understanding of the pharmacodynamic effects of MLN4924 that are responsible for its therapeutic activity in AML remains incomplete. We hypothesized that MLN4924 may augment the efficacy of ara-C based on its DNA damaging properties that we and others have reported. Our initial data supported this hypothesis. Yet, targeted knockdown of CDT1, a chromatin licensing factor and NEDD8 substrate that has been suggested to be a key mediator of MLN4924's DNA damaging properties and overall anticancer activity, did not indicate that it was an important regulator of sensitivity to the MLN4924/ara-C combination. We subsequently conducted global metabolic profiling of AML cells treated with MLN4924 to identify additional pharmacodynamic effects that may promote sensitization to ara-C. Our results showed that inhibition of NEDD8-mediated protein turnover has effects on multiple metabolic superpathways, but was particularly effective at antagonizing both purine and pyrimidine nucleotide metabolism. Although several preclinical studies have reported on the pharmacodynamic characteristics of MLN4924 (29), our investigation is the first to report the specific drug-related effects on nucleotide metabolism. In addition to establishing a new link between NEDD8-mediated protein turnover and nucleotide homeostasis, our findings demonstrate the value of global metabolic profiling in the pharmacodynamic analysis of investigational anticancer agents.
The MLN4924-induced disruption of nucleotide homeostasis that we observed provided a potential mechanistic explanation underlying its ability to improve the activity of the nucleoside analog ara-C. We hypothesized that the depletion of endogenous nucleotide pools by MLN4924 would yield more efficient incorporation of ara-C into the DNA of AML cells. A series of experiments demonstrated the benefit of the MLN4924/ara-C combination, which was due, at least in part, to MLN4924-mediated heightened incorporation of ara-C into DNA. This newly discovered DNA-related pharmacodynamic effect of MLN4924 builds upon several earlier investigations, which reported that the DNA damaging properties of MLN4924 are linked to the stabilization of the chromatin licensing factor CDT1 and subsequent DNA re-replication stress (14, 26, (30) (31) (32) .
Another interesting aspect of our study is related to the similar sensitivity of the primary AML cells from both newly diagnosed and previously treated AML patients to the MLN4924/ara-C combination. Although the number of specimens we analyzed is relatively small (n = 4 newly diagnosed, n = 6 previously treated), the benefit we observed in cells that were clinically refractory to the ara-C based "7+3" regimen could have important translational implications. It is possible that NEDDylation may play a previously unstudied role in ara-C resistance and that inhibiting the pathway with MLN4924 may be sufficient to counter resistance to ara-C and other anticancer agents.
Further investigation is required to fully evaluate this possibility, but the complete responses of refractory AML patients that were observed in the Phase I clinical trial of MLN4924 are encouraging (16) . Moreover, the ability of MLN4924 to antagonize drug resistance does not appear to be restricted to AML and/or the conventional agents that are used to treat this disease. We recently showed that MLN4924 re-sensitizes cisplatin-resistant ovarian cancer cells to platinum chemotherapy (17) . Our findings regarding the ability of MLN4924 to overcome platinum resistance were confirmed shortly after our initial report by an independent research team (33). These observations suggest that the mechanisms of resistance to MLN4924 do not directly overlap with those of cytotoxic chemotherapeutic agents and that NEDD8-mediated protein turnover may play a more significant role in controlling chemosensitivity than previously known.
At a minimum, these observations provide rationales to further explore potential applications for MLN4924 in the treatment of malignancies that are resistant to cytotoxic chemotherapy and to more rigorously study the mechanisms by which aberrant Author Manuscript Published OnlineFirst on November 11, 2014; DOI: 10.1158/1078-0432.CCR- research efforts with MLN4924, no specific predictive biomarker has been identified to date. The increasingly more powerful dataset that is developing as additional patients are treated with MLN4924 on clinical studies may help to address this issue.
In conclusion, our data establish that inhibition of NAE with MLN4924 is a novel strategy to augment the efficacy of ara-C. A clinical trial further investigating the safety and efficacy of MLN4924 in combination with ara-C therapy is warranted with ultimate comparison to LDAC monotherapy in older adults with AML. Considering the dramatic MLN4924-induced disruption of both purine and pyrimidine nucleotide metabolism we observed in this study, this approach may also have potential applications for other malignancies that use nucleoside analog-based therapy. Author Manuscript Published OnlineFirst on November 11, 2014; DOI: 10.1158/1078-0432.CCR- alkaline comet assay. Representative images are shown. n = 3 ± SD. *P < 0.05, indicates a significant difference from either single agent treatment. Fig. 3. CDT1 stabilization is not required for MLN4924 to augment ara-C activity. A, Knockdown of CDT1. Lentiviral shRNA was utilized to knockdown CDT1 expression.
Figure Legends
MOLM-13 cells infected with CDT1-directed or non-targeted control shRNA were treated with 100 nM MLN4924, 100 nM ara-C, or both drugs for 24 h. Knockdown efficiency was evaluated by immunoblotting. Tubulin documented equal protein loading.
B, CDT1 impairment does not significantly impact the pro-apoptotic effects of the MLN4924/ara-C combination. Cells infected with non-targeted control or CDT1 directed shRNA were treated with 100 nM MLN4924, 100 nM ara-C, or both drugs for 48 h. Drug-induced apoptosis was quantified by PI/FACS analysis. n = 3 ± SD. MOLM-13 and primary AML cells were treated with 100 nM MLN4924, 100 nM ara-C, 10 mM ribose or the indicated combinations for 48 h. Percentages of cells with subdiploid DNA were determined by PI/FACS. n = 3 ± SD, *P < 0.05 for the comparison between ara-C versus ara-C + ribose, **P < 0.05 for the comparison between ara-C + MLN4924 versus ara-C + MLN4924 + ribose. 
